Alzheimer Disease in the US Population

Hebert, Liesi E.; Scherr, Paul A.; Bienias, Julia L.; Bennett, David A.; Evans, Denis A.

doi:10.1001/archneur.60.8.1119

Cited by 1,886 publications

(550 citation statements)

References 15 publications

Supporting

Mentioning

543

Contrasting

Unclassified

Order By: Relevance

“…It is estimated that 10% of people over the age of 65 are affected by AD 4 and by 2050, the number of people with AD in the US will increase threefold. 45 The definite diagnosis of AD is made upon histological verification, established by biopsy or at autopsy, of two main hallmarks: extracellular amyloid plaques and intracellular neurofibrillary tangles, which enclose hyperphosphorylated tau protein. 26,102 Furthermore, the neuropathology of AD is characterized by a progressive loss of synapses and neurons in a region-and celltype-specific manner.…”

Section: Alzheimer Diseasementioning

confidence: 99%

Nanoparticle transport across the blood brain barrier

et al. 2016

View full text Add to dashboard Cite

While the role of the blood-brain barrier (BBB) is increasingly recognized in the (development of treatments targeting neurodegenerative disorders, to date, few strategies exist that enable drug delivery of non-BBB crossing molecules directly to their site of action, the brain. However, the recent advent of Nanomedicines may provide a potent tool to implement CNS targeted delivery of active compounds. Approaches for BBB crossing are deeply investigated in relation to the pathology: among the main important diseases of the CNS, this review focuses on the application of nanomedicines to neurodegenerative disorders (Alzheimer, Parkinson and Huntington's Disease) and to other brain pathologies as epilepsy, infectious diseases, multiple sclerosis, lysosomal storage disorders, strokes.

show abstract

Section: Alzheimer Diseasementioning

confidence: 99%

Nanoparticle transport across the blood brain barrier

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In 2016, there were approximately 5.4 million persons with AD in the US population. By 2050, this number is expected to increase by almost threefold, to 13.2 million (Hebert, Scherr, Bienias, Bennett, & Evans, 2003). …”

Section: Introductionmentioning

confidence: 99%

High‐fat diet protects the blood–brain barrier in an Alzheimer's disease mouse model

et al. 2018

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is associated with increased risk of Alzheimer's disease (AD). There is evidence for impaired blood–brain barrier (BBB) in both diseases, but its role in the interplay between them is not clear. Here, we investigated the effects of high‐fat diet (HFD), a model for T2D, on the Tg2576 mouse model of AD, in regard to BBB function. We showed that HFD mice had higher weight, more insulin resistance, and higher serum HDL cholesterol levels, primarily in Tg2576 mice, which also had higher brain lipids content. In terms of behavior, Tg2576 HFD mice were less active and more anxious, but had better learning in the Morris Water Maze compared to Tg2576 on regular diet. HFD had no effect on the level of amyloid beta 1–42 in the cortex of Tg2576 mice, but increased the transcription level of insulin receptor in the hippocampus. Tg2576 mice on regular diet demonstrated more BBB disruption at 8 and 12 months accompanied by larger lateral ventricles volume in contrast to Tg2576 HFD mice, whose BBB leakage and ventricular volume were similar to wild‐type (WT) mice. Our results suggest that in AD, HFD may promote better cognitive function through improvements of BBB function and of brain atrophy but not of amyloid beta levels. Lipid metabolism in the CNS and peripheral tissues and brain insulin signaling may underlie this protection.

show abstract

“…The most prevalent form of MND is Alzheimer's disease (60-80%) [2]. It is estimated that 6.7 million individuals in the U.S over 65 years of age will have Alzheimer's disease by 2025 [2].…”

Section: Functional Task Batterymentioning

confidence: 99%

Functional NeuroCognitive ImagingTM and Notus NeuroCogsTM: A Novel Use of fMRI in the Assessment of Cognitive Function in Major Neurocognitive Disorder

Epps¹,

Tucker²,

Fong³

et al. 2017

J Neuroimaging Psychiatry Neurol

View full text Add to dashboard Cite

Background: Current diagnostic approaches to MND rely heavily upon the history of present illness and neurocognitive testing with functional neuroimaging playing a minimal role. The use of fMRI as a clinical tool has been limited due to the lack of a standardized protocol of cognitive testing appropriate for the scanning environment and lack of normalized data to which the individual patient can be compared. We therefore present Functional NeuroCognitive Imaging

show abstract

Alzheimer Disease in the US Population

Abstract: The number of persons with AD in the US population will continue to increase unless new discoveries facilitate prevention of the disease.

Cited by 1,886 publications

References 15 publications

Nanoparticle transport across the blood brain barrier

Nanoparticle transport across the blood brain barrier

High‐fat diet protects the blood–brain barrier in an Alzheimer's disease mouse model

Functional NeuroCognitive ImagingTM and Notus NeuroCogsTM: A Novel Use of fMRI in the Assessment of Cognitive Function in Major Neurocognitive Disorder

Contact Info

Product

Resources

About